Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07388264 · ClinicalTrials.gov registry record · NA
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
A NA study of Constipation and Gut Health, sponsored by Lindenwood University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07388264 is a NA study of Constipation and Gut Health that is actively recruiting participants, run by Lindenwood University. The registered enrollment target is 30 participants, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07388264, a NA study of Constipation and Gut Health, is actively recruiting participants, sponsored by Lindenwood University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related gastrointestinal function compared with placebo. Approximately 30 healthy men and women aged 18 to 50 years will be enrolled in a randomized, double-blind, placebo-controlled, crossover trial. Participants will complete two 4-week supplementation periods, one with Weizmannia (Bacillus) coagulans JBI-YZ6.3 and one with placebo, separated by a 4-week washout period. The total duration of participation will be approximately 13 to 14 weeks, including screening and testing visits. Gastrointestinal symptoms will be assessed at baseline and after each supplementation period using validated questionnaires, with particular focus on the constipation domain of the Gastrointestinal Symptom Rating Scale (GSRS). Secondary outcomes will include additional gastrointestinal symptom domains and markers of perceived gut comfort and function. This study is designed to determine whether supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 produces clinically meaningful improvements in gastrointestinal symptoms in physically active adults compared with placebo.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Weizmannia (Bacillus) coagulans JBI-YZ6.3
Study Locations (1)
Missouri
- Lindenwood University - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2026-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07388264
The ClinicalTrials.gov registry entry for NCT07388264 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (85% lower). The listed sponsor is Lindenwood University, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Constipation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07388264 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT07388264 about?
NCT07388264 is a clinical study titled "Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes". This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related ga...
What is the current status of trial NCT07388264?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-15. Estimated completion is 2026-06-15.
What conditions does trial NCT07388264 study?
This clinical trial studies the following conditions: Constipation, Gut Health, Gastrointestinal Symptoms, Gastrointestinal Function.
What interventions are being tested in trial NCT07388264?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Weizmannia (Bacillus) coagulans JBI-YZ6.3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07388264?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07388264 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Management of Dyssynergic Defecation
RECRUITING · NA
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
RECRUITING · NA
-
Understanding Mechanisms of Normal and Disordered Defecation
RECRUITING · NA
-
Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.